Anti‐hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV‐infected patients
Yves Benhamou, Herve Fleury, Pascale Trimoulet, Isabelle Pellegrin, Renaud Urbinelli, Christine Katlama, Willy Rozenbaum, Gwenael Le Teuff, Aldo Trylesinski, Christophe Piketty – 22 February 2006 – Tenofovir disoproxil fumarate (TDF) has shown in vitro activity against both HIV and hepatitis B virus (HBV). We retrospectively evaluated the efficacy of TDF (300 mg/d), administered as a part of anti‐retroviral therapy, in a large cohort of HIV/HBV‐coinfected patients.